CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma
Plain-language summary
This trial is testing CD7-directed CAR-T cell therapy for patients with anaplastic large cell lymphoma (ALCL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years to 75 Years years
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
CD70-targeting CAR-T cells (BIOLOGICAL): Dose escalation: Dose1 (1×10\^6 cells/kg) ,Dose 2(3×10\^6 cells/kg) ,Dose 3 (1×10\^7 cells/kg) Doseexpansion: RP2D Drug: Fludarabine Intravenous fludarabine 25-30 mg/m\^2/day on days 5, -4, and -3. Drug: Cyclophosphamide Intravenous cyclophosphamide 300-500 mg/m\^2/day on days -5, -4, and -3.
CD70-targeting CAR-T cells
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details